AstraZeneca PLC's aim of securing the market-leading position of its biggest seller Tagrisso has received a major boost with the release of late-stage data demonstrating the additional benefit of combining the drug with chemotherapy for lung cancer patients.
AstraZeneca Lifted By Tagrisso Combo Lung Cancer Data
Shows Improvement Over Monotherapy
Data from the FLAURA2 trial suggest AstraZeneca could soon be able to expand use of Tagrisso in the first-line setting, widening the gap over Johnson & Johnson’s Rybrevant.
